Summary: The Centers for Medicare & Medicaid Services modified its coverage policy for Partial Thromboplastin Time (PTT) testing, effective May 15, 2026. Here's what billing teams need to do.
CMS updated its PTT coverage policy — one of the foundational lab tests used to evaluate coagulation disorders and monitor anticoagulant therapy. This policy does not carry a numbered policy code in the CMS system. The policy document does not list specific CPT or HCPCS codes, so this post covers the clinical and billing context your team needs to prepare before the May 15, 2026 effective date.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | CMS (Centers for Medicare & Medicaid Services) |
| Policy | Partial Thromboplastin Time (PTT) |
| Policy Code | N/A |
| Change Type | Modified |
| Effective Date | May 15, 2026 |
| Impact Level | Medium |
| Specialties Affected | Clinical laboratory, hematology, internal medicine, cardiology, hospital outpatient, anticoagulation management |
| Key Action | Audit PTT claims for medical necessity documentation before May 15, 2026 |
CMS Partial Thromboplastin Time Coverage Criteria and Medical Necessity Requirements 2026
The CMS PTT coverage policy governs when Medicare will pay for Partial Thromboplastin Time testing. PTT — sometimes called aPTT (activated partial thromboplastin time) — measures how long blood takes to clot through the intrinsic pathway. CMS considers it medically necessary in specific clinical contexts. Outside those contexts, expect a claim denial.
The policy document does not list specific CPT or HCPCS codes. Your billing team should confirm the exact codes your lab uses for PTT testing against your Medicare Administrative Contractor's local coverage determination (LCD). MACs frequently publish LCDs that layer additional criteria on top of CMS national policy, and those LCD-level rules carry the same claim denial risk.
Medical necessity is the central issue with PTT billing under Medicare. CMS ties reimbursement to documented clinical indications. Common covered indications — based on established CMS medical necessity principles and clinical standards — include monitoring patients on unfractionated heparin therapy, evaluating suspected coagulopathy, working up bleeding disorders, and pre-surgical coagulation screening when clinically indicated. The operative word is "clinically indicated." Routine or standing orders without documented clinical rationale have long been a denial target under this coverage policy.
If your facility runs PTT as part of a reflex panel or standard admission order without individualized documentation, that's your highest-risk scenario. Prior authorization is not typically required for routine lab testing under Medicare Part B, but medical necessity documentation is non-negotiable. Your ordering providers need to document the specific clinical reason for each PTT order in the patient record — not a generic "coagulation screen" note.
CMS PTT Exclusions and Non-Covered Indications
CMS does not cover PTT testing ordered without documented medical necessity. That sounds simple, but it's where most claims fall apart.
Screening PTT in asymptomatic patients without a clinical indication is not covered. Pre-op PTT ordered as a standing protocol — rather than in response to a specific patient history or clinical finding — has been a consistent denial source across MAC jurisdictions. CMS has long held that blanket pre-surgical coagulation panels don't meet medical necessity criteria unless the patient has a documented bleeding history or is on anticoagulant therapy.
Repeat PTT testing without documented therapeutic changes or clinical reassessment is another non-covered scenario. If your facility bills multiple PTT tests on the same day or in rapid succession, each one needs its own clinical justification in the record. "Repeat per protocol" doesn't cut it.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Monitoring unfractionated heparin therapy | Covered | Not specified in policy | Requires documentation of heparin therapy and dose adjustment |
| Evaluation of suspected coagulopathy | Covered | Not specified in policy | Clinical signs/symptoms must be documented |
| Bleeding disorder workup | Covered | Not specified in policy | Document clinical presentation and history |
| Pre-surgical coagulation screening (with documented clinical indication) | Covered | Not specified in policy | Must have documented bleeding history or anticoagulant use |
| Routine pre-surgical screening (no clinical indication) | Not Covered | Not specified in policy | Standing protocol orders without individual documentation denied |
| Screening in asymptomatic patients | Not Covered | Not specified in policy | No documented clinical reason = no coverage |
| Repeat testing without documented clinical change | Not Covered | Not specified in policy | Each repeat test requires its own documented rationale |
The policy does not list specific CPT or HCPCS codes. Check with your MAC for applicable code-level guidance.
CMS Partial Thromboplastin Time Billing Guidelines and Action Items 2026
The modified policy takes effect May 15, 2026. That gives you a defined window to get your documentation and billing processes in order. Here's what to do.
| # | Action Item |
|---|---|
| 1 | Audit your current PTT order patterns before May 15, 2026. Pull 90 days of PTT claims and look at the ordering patterns. Flag any standing orders, blanket pre-op protocols, or repeat testing without clear clinical triggers. Those are your highest denial-risk claims going forward. |
| 2 | Check with your MAC for applicable CPT and HCPCS codes. The CMS policy document does not list specific codes. Contact your Medicare Administrative Contractor directly or review their LCD for PTT testing to confirm which codes this modified coverage policy governs. Your reimbursement depends on billing the right code with the right documentation. |
| 3 | Update your order entry templates to require a clinical indication field. If your EHR or lab order system allows standing PTT orders without a documented reason, that's a process gap. Work with your informatics or clinical team to require a structured indication before the order completes. This is your best upstream defense against claim denial. |
| 4 | Train ordering providers on medical necessity documentation requirements. "Monitoring anticoagulation" is sufficient. "Coagulation screen" is not. The distinction seems minor — it isn't. CMS reviewers look for specific language tying the test to the patient's current clinical status. Send a one-page documentation guide to your highest-volume ordering providers before May 15, 2026. |
| 5 | Review your anticoagulation clinic billing workflows separately. If your facility runs a dedicated anticoagulation management program, PTT billing guidelines there may interact with other CMS policies on chronic care and anticoagulation management services. Confirm your billing team knows how PTT claims in that setting are documented and coded. If there's any overlap with bundled service codes, loop in your compliance officer before the effective date. |
| 6 | Pull a post-implementation audit in June 2026. Set a reminder now. Run a denial report on PTT claims from May 15 through June 30. If denial rates spike, you'll want to catch that early — not at quarter-end. Early detection means faster appeals and faster documentation fixes. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Partial Thromboplastin Time Under This Policy
The CMS policy document for this PTT modification does not list specific CPT, HCPCS, or ICD-10 codes. Including invented codes here would be worse than useless — it would cost your team time and money when those claims hit edits.
What You Should Do Instead
Contact your MAC directly and ask for the LCD governing PTT testing in your jurisdiction. Different MACs have different LCDs, and the local coverage determination is where you'll find the actual code-level criteria, covered diagnoses, and billing restrictions that apply to your claims.
The most commonly used CPT code for PTT testing in clinical practice is broadly referenced in laboratory billing literature — but because this policy document does not confirm it, your billing team should verify the specific code with your MAC rather than rely on assumption. One wrong code means one more denial to work.
For ICD-10-CM diagnosis codes, the same principle applies. Medical necessity documentation needs to map to a diagnosis that CMS recognizes as a covered indication. Your MAC's LCD will list the covered ICD-10 codes. Make sure your charge capture links the correct diagnosis to each PTT order.
If you're unsure how this modified coverage policy maps to your lab's current CPT and diagnosis code mix, talk to your compliance officer or billing consultant before May 15, 2026. The effective date is fixed. The risk of billing against the modified policy without confirming your code set is real.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.